American Express Co vs Neurocrine Biosciences Inc — how do they compare? American Express Co trades at $343.84 (market cap $230.15B), while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: American Express Co is far larger — about 14× Neurocrine Biosciences Inc's market cap, and American Express Co pays a 1.11% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AXP | NBIX | |
|---|---|---|
Market Cap | $230.15B | $16.46B |
Sector | Financials | Health |
52-Week High | $384.82 | $185.50 |
52-Week Low | $292.27 | $123.10 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $16.48B |
Signals from Pluang's Aura AI — not financial advice
AXP trades at $343.22, up 1.29% today, with a bullish technical signal and strong support at $339. The stock shows robust fundamentals with 2025 revenue of $72.23B and net income of $10.83B, though recent earnings have been mixed. Analyst consensus is a $369.42 price target with 40% buy ratings. Recent news highlights Amex Ventures' AI investments and premium cardmember benefits, reinforcing growth initiatives.
Outlook remains positive due to steady revenue growth and high ROE of 33.97%, but risks include competitive pressures and a P/E of 20.68 above sector averages. The stock offers upside to consensus targets if execution continues, though investors should monitor spending trends and economic sensitivity.
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →